WHO Wrestles With Engagement Of “Non-State Actors” 25/06/2013 by Brittany Ngo for Intellectual Property Watch Leave a Comment The World Health Organization is undergoing major reform including working to stabilise its fiscal future, and members are trying to set out careful terms for working with and receiving support from entities referred to as non-state actors, such as private foundations and organisations.
US Gives Boost To Materials Genome Initiative 24/06/2013 by Intellectual Property Watch Leave a Comment The Obama administration and academic and industry partners today announced their commitment to support the Materials Genome Initiative (MGI), a public-private endeavor whose aim is to reduce the time required to develop novel materials that can “fuel advanced manufacturing and bolster the 21st century American economy.”
WHO Restructures Medicines Department, Including Innovation, Policy 24/06/2013 by Brittany Ngo for Intellectual Property Watch Leave a Comment This summer through September, a restructuring is taking place under the World Health Organization Health Systems and Innovation cluster that has relevance for intellectual property and innovation issues.
UNICEF Supply Annual Report Highlights Medical Products Access, Innovation 21/06/2013 by Brittany Ngo for Intellectual Property Watch Leave a Comment In its recently released Supply Annual Report for 2012, the United Nations agency UNICEF assessed its programme work in developing and strengthening supply chains, in hopes of achieving equitable access to life-saving supplies for children and women. The report found that UNICEF procured supplies and services valued at $2.468 billion, with India being the largest supplier country to UNICEF in 2012.
Asia-Pacific Region Vies For Biotechnology Industry Opportunities 20/06/2013 by Daria Kim for Intellectual Property Watch Leave a Comment Hong Kong – A recent conference here looked at the evolving biotechnology landscape in the Asia-Pacific region as well as prospects for networking and raising capital for early stage life science innovation.
European Commission Fines Pharma Companies For Payments To Delay Generic Entry 19/06/2013 by Brittany Ngo for Intellectual Property Watch 1 Comment The European Commission (EC) has fined Danish pharmaceutical company Lundbeck as well as eight other generic manufacturers for delaying market entry of generic medicines by way of patent settlement agreements (also known as “pay-for-delay” agreements).
The Impact Of Derailing The WHO Medical R&D Convention 19/06/2013 by Intellectual Property Watch 1 Comment An article in the newly launched Journal of Health Diplomacy about the stalled progress at the World Health Organization for a medical research and development (R&D) convention discusses systemic failures in global health policy.
WIPO Seminar Discusses Impact Of TRIPS On Pharmaceutical Innovation 19/06/2013 by Brittany Ngo for Intellectual Property Watch Leave a Comment The latest instalment of the World Intellectual Property Organization seminar series titled “The Economics of Intellectual Property” covered the issue of product patents in the pharmaceutical industry. Discussion focussed on the economics of intellectual property rights and how pharmaceutical patent protection might not be the sole culprit in the access to innovation problem.
US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market 17/06/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs’ entry into the market may not be immune from antitrust scrutiny but are not “presumptively” unlawful. The case was sent back to lower court.
US Supreme Court Restricts Gene Patents … A Little 17/06/2013 by Steven Seidenberg for Intellectual Property Watch 2 Comments Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.